Comparison · NCT00498797-597872b9
Vandetanib vs Placebo: Number of Patients With an Objective Disease Progression Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib vs Placebo: Number of Patients With an Objective Disease Progression Event. Trial comparisons, record NCT00498797-597872b9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00498797-597872b9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.651 | 0.502 | 0.776 | wilson | |
| Risk in group 2 | 0.605 | 0.456 | 0.736 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0465 | -0.153 | 0.241 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.777 | 1.49 | log | |
| Odds ratio, group 1 over group 2 | 1.22 | 0.508 | 2.93 | log | |
| Number needed to treat, for one more participant with the outcome on Vandetanib than on Placebo | 21.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib | docetaxel/prednisolone/vandetanib | 28 | 43 | OG000 |
| Group 2 | Placebo | docetaxel/prednisolone/placebo | 26 | 43 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With an Objective Disease Progression Event
- Description
- Number of patients with objective disease progression or death (by any cause in the absence of objective progression)
- Time frame
RECIST tumour assessments carried out at screening and then as per site clinical practice until objective progression. The only additional mandatory tumour assessment visit is at the point of data cut-off (21 July 2007 or up to 7 days in advance of DCO)
- Population
Source ClinicalTrials.gov
Trial
- Title
- E3-Hormone Refractory Prostrate Cancer Taxotere Combination
- NCT number
- NCT00498797
- Phases
- PHASE2
- Conditions
- Prostate Cancer, Metastatic, Hormone Refractory
- Interventions
- Zactima (vandetanib), Docetaxel, Prednisolone
- Lead sponsor
- Sanofi
- Results first posted
- 2011-05-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00498797?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00498797-597872b9